126 related articles for article (PubMed ID: 37935621)
1. Correction to: An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results.
J Appl Lab Med; 2024 May; 9(3):658. PubMed ID: 37935621
[No Abstract] [Full Text] [Related]
2. An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results.
Geno KA; Badea A; Lynch KL; Jannetto P; Hubbard JA; Nerenz RD; Cervinski MA
J Appl Lab Med; 2022 Oct; 7(6):1318-1328. PubMed ID: 36036092
[TBL] [Abstract][Full Text] [Related]
3. Loperamide-Associated Opioid Use Disorder and Proposal of an Alternative Treatment with Buprenorphine.
Wolfrum LA; Nordmeyer AS; Racine CW; Nichols SD
J Addict Med; 2019; 13(3):245-247. PubMed ID: 30379781
[TBL] [Abstract][Full Text] [Related]
4. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.
Elkiweri IA; Zhang YL; Christians U; Ng KY; Tissot van Patot MC; Henthorn TK
Anesth Analg; 2009 Jan; 108(1):149-59. PubMed ID: 19095843
[TBL] [Abstract][Full Text] [Related]
5. Long-term Buprenorphine Treatment for Loperamide Use Disorder: A Case Series.
Brar JK; Broyan VR; Allgaier JT; Nye L; Saxon AJ
J Addict Med; 2020 Dec; 14(6):e378-e381. PubMed ID: 32530885
[TBL] [Abstract][Full Text] [Related]
6. Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients.
Moss LM; Algera MH; Dobbins R; Gray F; Strafford S; Heath A; van Velzen M; Heuberger JAAC; Niesters M; Olofsen E; Laffont CM; Dahan A; Groeneveld GJ
PLoS One; 2022; 17(1):e0256752. PubMed ID: 35085249
[TBL] [Abstract][Full Text] [Related]
7. Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence.
Wakeman SE; Chang Y; Regan S; Yu L; Flood J; Metlay J; Rigotti N
J Addict Med; 2019; 13(4):253-257. PubMed ID: 30550392
[TBL] [Abstract][Full Text] [Related]
8. Modeling buprenorphine reduction of fentanyl-induced respiratory depression.
Olofsen E; Algera MH; Moss L; Dobbins RL; Groeneveld GJ; van Velzen M; Niesters M; Dahan A; Laffont CM
JCI Insight; 2022 May; 7(9):. PubMed ID: 35316224
[TBL] [Abstract][Full Text] [Related]
9. Opioid-induced respiratory effects: new data on buprenorphine.
Dahan A
Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
[TBL] [Abstract][Full Text] [Related]
10. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips.
Lockwood TE; Vervoordt A; Lieberman M
Harm Reduct J; 2021 Mar; 18(1):30. PubMed ID: 33750405
[TBL] [Abstract][Full Text] [Related]
11. Legal Limitations Associated with Microdosing Buprenorphine.
Andraka-Christou B; Evans MD; Tranen B; Mendoza NS
Subst Use Misuse; 2023; 58(7):956-959. PubMed ID: 37026431
[No Abstract] [Full Text] [Related]
12. Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl.
Spadaro A; Sarker A; Hogg-Bremer W; Love JS; O'Donnell N; Nelson LS; Perrone J
Clin Toxicol (Phila); 2022 Jun; 60(6):694-701. PubMed ID: 35119337
[TBL] [Abstract][Full Text] [Related]
13. Non-prescription Fentanyl Positive Toxicology: Prevalence, Positive Predictive Value of Fentanyl Immunoassay Screening, and Description of Co-substance Use.
Kerensky T; LaRochelle M; Fan SL; Kosakowski S; Wason K; Walley AY
J Addict Med; 2021 Apr; 15(2):150-154. PubMed ID: 32909981
[TBL] [Abstract][Full Text] [Related]
14. The effects of buprenorphine on fentanyl withdrawal in rats.
Bruijnzeel AW; Marcinkiewcz C; Isaac S; Booth MM; Dennis DM; Gold MS
Psychopharmacology (Berl); 2007 May; 191(4):931-41. PubMed ID: 17211652
[TBL] [Abstract][Full Text] [Related]
15. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
[TBL] [Abstract][Full Text] [Related]
16. Community based buprenorphine micro-induction in the context of methadone maintenance treatment and fentanyl - Case report.
Kaliamurthy S; Jegede O; Hermes G
J Addict Dis; 2023; 41(2):175-180. PubMed ID: 35377273
[TBL] [Abstract][Full Text] [Related]
17. Partial versus full agonists for opioid-mediated analgesia--focus on fentanyl and buprenorphine.
Zuurmond WW; Meert TF; Noorduin H
Acta Anaesthesiol Belg; 2002; 53(3):193-201. PubMed ID: 12461829
[TBL] [Abstract][Full Text] [Related]
18. Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats.
Hammerslag LR; Hofford RS; Kang Q; Kryscio RJ; Beckmann JS; Bardo MT
Drug Alcohol Depend; 2020 Feb; 207():107804. PubMed ID: 31862556
[TBL] [Abstract][Full Text] [Related]
19. Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates.
Butelman ER; Harris TJ; Kreek MJ
J Pharmacol Exp Ther; 2004 Oct; 311(1):155-63. PubMed ID: 15152028
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
